Skip to main content
. 2020 May 24;25(9):1736–1743. doi: 10.1007/s10147-020-01699-6

Fig. 3.

Fig. 3

Overall survival with tisagenlecleucel by best overall response. CR complete response, DLBCL diffuse large B-cell lymphoma, OS overall survival, PR partial response, tMALT transformed mucosa-associated lymphoid tissue lymphoma